Software as a Medical Device (SAMD): Clinical Evaluation Guidance for Industry and Food and Drug Administration Staff December 2017
- Docket Number:
- Issued by:
Guidance Issuing OfficeCenter for Devices and Radiological Health
IMDRF is a voluntary group of medical device regulators from around the world who have come together to accelerate international medical device regulatory harmonization and convergence. The IMDRF Management Committee (IMDRF MC) chartered the SaMD Working Group (WG) to develop a regulatory framework for SaMD and to develop converged principles for global regulators to adopt in their respective jurisdictions. This IMDRF document has been unanimously approved by the IMDRF MC. For more information on IMDRF activities, please see http://www.imdrf.org/index.asp.
This guidance adopts the internationally converged principles agreed upon by the IMDRF. FDA adoption of these principles provides FDA with an initial framework when further developing FDA’s specific regulatory approaches and expectations for regulatory oversight. This guidance does not provide recommendations for FDA Staff and Industry to apply to specific regulatory situations, nor does it modify current regulatory expectations, including those for regulatory submissions, at this time. The words require or requirements used in this document do not reflect FDA regulatory requirements and are intended only to be considerations for Industry and FDA staff. FDA intends to consider the principles of this guidance in the development of regulatory approaches for SaMD and digital health technologies. In developing regulatory approaches based on the principles of this guidance, the agency intends to follow a public process, including providing opportunities for public input. For more information on FDA adoption of IMDRF documents as an FDA guidance document, please see International Medical Device Regulators Forum (IMDRF).
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2016-D-2483.